Last reviewed · How we verify

David Rizzieri, MD — Portfolio Competitive Intelligence Brief

David Rizzieri, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alexion Pharmaceuticals, Inc. · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
  4. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  5. Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
  6. Baxalta now part of Shire · 1 shared drug class
  7. Bayer · 1 shared drug class
  8. AgeneBio · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for David Rizzieri, MD:

Cite this brief

Drug Landscape (2026). David Rizzieri, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/david-rizzieri-md. Accessed 2026-05-17.

Related